Compare Merck & Co., Inc. (MRK) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Merck & Co., Inc. trades at $133.05 (market cap $321.77B), while Direxion Daily S&P 500 Bull 3X Shares trades at $296.01. The key difference: Merck & Co., Inc. pays a 2.61% dividend while Direxion Daily S&P 500 Bull 3X Shares pays none. Which is the better fit depends on your goals.
| MRK | SPXL | |
|---|---|---|
Market Cap | $321.77B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $132.93 | $296.39 |
52-Week Low | $77.60 | $170.20 |
Enterprise Value | $368.53B | — |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue reached $65.01B in 2025, and net income margin improved to 28.07%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, supported by analyst consensus favoring a buy rating (67.57%) and a price target of $140.36. Key opportunities include pipeline expansion through M&A and solid cash flow generation. Risks involve high valuation multiples, such as a P/E of 104.34, and potential integration challenges from acquisitions. Investors should weigh growth prospects against elevated earnings expectations and market volatility.
SPXL trades at $295.39, down 0.27% in the last session, with technical indicators showing a bullish trend from moving averages but overbought signals from RSI levels above 70. The stock's pivot point at $294 and resistance at $296 suggest near-term price sensitivity. Recent news highlights S&P 500 record highs and AI-driven earnings optimism, though valuation concerns persist.
Outlook remains cautiously optimistic amid strong market momentum, with opportunities from AI growth and corporate earnings, but risks include high valuations and potential pullbacks. Investors should balance bullish technicals with fundamental prudence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
